Myrto KOROGIANNAKΙ – who developed a contact lens-based drug delivery system for glaucoma patients – is a graduate of the University of Patras holding a diploma from the Department of Chemical Engineering, University of Patras (2010).

 

In 2015, while being a PhD candidate at McMaster University (2012-2016) she harnessed a component naturally found in tears to develop a contact lens-based drug delivery system for glaucoma patients. She is one of a number of researchers in the Department of Chemical Engineering in Heather Sheardown’s lab looking at more effective ways of delivering drugs to both the front and back of the eye. In 2012, her team developed a microneedle system that could painlessly deliver medication to the back of the eye, sparing patients the excruciating routine of having drugs injected into their eyes by syringe every six to eight weeks. In 2015, Sheardown was named Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery Systems and works to develop biomaterials for contact or implanted lenses and new formulas for topical drops.

 

More:

https://medicalxpress.com/news/2015-06-chemical-contacts-glaucoma.html

https://www.ellines.com/en/achievements/23235-she-developed-contact-lenses-for-glaucoma-patients/

 

Myrto KOROGIANNAKΙ – who developed a contact lens-based drug delivery system for glaucoma patients – is a graduate of the University of Patras holding a diploma from the Department of Chemical Engineering, University of Patras (2010).

 

In 2015, while being a PhD candidate at McMaster University (2012-2016) she harnessed a component naturally found in tears to develop a contact lens-based drug delivery system for glaucoma patients. She is one of a number of researchers in the Department of Chemical Engineering in Heather Sheardown’s lab looking at more effective ways of delivering drugs to both the front and back of the eye. In 2012, her team developed a microneedle system that could painlessly deliver medication to the back of the eye, sparing patients the excruciating routine of having drugs injected into their eyes by syringe every six to eight weeks. In 2015, Sheardown was named Canada Research Chair in Ophthalmic Biomaterials and Drug Delivery Systems and works to develop biomaterials for contact or implanted lenses and new formulas for topical drops.

 

More:

https://medicalxpress.com/news/2015-06-chemical-contacts-glaucoma.html

https://www.ellines.com/en/achievements/23235-she-developed-contact-lenses-for-glaucoma-patients/

 

Read more